Latest Biotech News

Recursion announced a planned leadership transition: long‑time CEO Chris Gibson will become board chair and Najat Khan, PhD, the company’s chief R&D and commercial officer, will assume CEO...

Researchers at the University of Duisburg‑Essen developed an automated stirred‑tank bioreactor process to generate large quantities of iPSC‑derived lung organoids, producing complex...

Regeneron Pharmaceuticals struck a $150 million collaboration with Tessera Therapeutics to develop and commercialize TSRA-196, a near-clinic in vivo gene-writing candidate for alpha-1 antitrypsin...

Protego Biopharma closed a $130 million oversubscribed Series B led by Novartis Venture Fund and Forbion to advance its first-in-class oral program for light‑chain (AL) amyloidosis into a...

Belite Bio reported topline success from its 104-subject Phase 3 DRAGON trial: tinlarebant produced a statistically significant 36% reduction in the growth rate of retinal lesions versus placebo...

The FDA approved Novartis’ intrathecally delivered SMA gene therapy Itvisma (onasemnogene abeparvovec), offering a new delivery route intended to broaden access beyond the intravenous label of...

The U.K. government agreed to loosen drug-price controls and increase medicine spending in return for a three‑year exemption from potential U.S. tariffs on British pharmaceuticals under Section...

China’s National Medical Products Administration authorized Innovent Biologics’ picankibart (IBI‑112), branded Pecondle, for moderate to severe plaque psoriasis—marking the country’s first...

Generate:Biomedicines announced initiation of two large Phase 3 trials for its lead TSLP antibody, advancing the company’s first program from discovery to pivotal development. The move underscores...

Ideaya Biosciences received FDA clearance to begin a Phase I trial of IDE‑034, a bispecific antibody‑drug conjugate targeting B7H3/PTK7 linked to a TOP1 payload, for solid tumors. The...

Precision Health Research, Singapore (PRECISE) formalized a precompetitive partnership with Alnylam, Bayer, Boehringer Ingelheim and Novo Nordisk to analyze data from PRECISE‑SG100K, a population...

Janux Therapeutics disclosed a new data cut from its Phase 1 study of JANX007, a T‑cell engager for prostate cancer, showing a 30% objective response rate in the evaluated cohort. The company...

Protego Biopharma closed an oversubscribed $130 million financing to advance its first‑in‑class oral program for light‑chain (AL) amyloidosis into a potential pivotal study next year. The round...

Regeneron Pharmaceuticals and Tessera Therapeutics struck a collaboration valued at $150 million to develop and commercialize TSRA‑196, Tessera’s in‑vivo gene‑writing candidate for alpha‑1...

Belite Bio reported topline results from the global Phase 3 DRAGON trial showing that tinlarebant met the study’s primary endpoint in adolescents with Stargardt disease type 1 (STGD1). The company...

Generate:Biomedicines announced the start of two large Phase 3 trials for its lead TSLP (thymic stromal lymphopoietin) antibody, marking a key clinical inflection for the AI‑driven biotech. The...

Circular Genomics raised $15 million in a Series A round led by Mountain Group Partners to advance a circular RNA (circRNA)‑based biomarker platform for early detection of Alzheimer’s disease. The...

Morphocell Technologies announced a $50 million Series A financing extension — a $10 million add‑on to its earlier $40 million close — led by Investissement Québec with participation from CDP...

JP Morgan, BTIG and Jefferies initiated analyst coverage on molecular diagnostics firm BillionToOne, assigning a range of ratings and price targets that reflect optimism about the company’s...

Ideaya Biosciences received FDA IND clearance to begin a Phase I study of IDE‑034, a bispecific antibody‑drug conjugate targeting B7H3/PTK7 coupled to a TOP1 payload, in patients with advanced...